| 17 Jun, 05:07 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 17 Jun, 05:05 pm | — | … | Lupin Limited has informed the Exchange regarding a press release dated June 17, 2026, titled "Lupin Launches Azilsartan Medoxomil Tablets in the United States". | nse |
| 08 Jun, 12:19 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 08 Jun, 12:13 pm | — | … | Lupin Limited has informed the Exchange regarding a press release dated Jun 08, 2026, titled "Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain". | nse |
| 04 Jun, 11:06 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 04 Jun, 10:59 pm | — | … | Lupin Limited has informed the Exchange regarding a press release dated Jun 04, 2026, titled " Lupin Receives Approval from U.S. FDA for Ranluspec (ranibizumab) Injection". | nse |
| 03 Jun, 11:02 am | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 03 Jun, 11:01 am | — | … | Lupin Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection". | nse |
| 29 May, 07:04 pm | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 29, 2026, titled "Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets". | nse |
| 29 May, 07:03 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 29 May, 03:59 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Updates on Acquisition | bse |
| 29 May, 03:59 pm | — | … | Lupin Limited has informed the Exchange about update on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. | nse |
| 28 May, 11:20 am | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 28 May, 11:10 am | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026". | nse |
| 28 May, 09:51 am | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 28 May, 09:48 am | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Lupin s Ankleshwar Facility Receives EIR from U.S. FDA". | nse |
| 22 May, 03:54 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 22 May, 03:48 pm | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension". | nse |
| 20 May, 04:03 pm | — | … | Lupin Ltd - 500257 - Compliances-Reg.24(A)-Annual Secretarial Compliance | bse |
| 19 May, 11:45 am | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 19 May, 11:43 am | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Lupin Makes its Debut in Dow Jones Best-in-Class Indices 2026". | nse |
| 18 May, 09:11 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 18 May, 09:08 pm | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 18, 2026, titled "Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution". | nse |
| 15 May, 11:17 am | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 15 May, 11:11 am | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Lupin Inaugurates Atharv Ability, an Advanced Multidisciplinary Neuro-Rehabilitation Center in Delhi". | nse |
| 14 May, 05:11 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | bse |
| 14 May, 05:09 pm | — | … | Lupin Limited has informed the Exchange about Transcript of Q4 FY2026 Earnings Conference Call. | nse |
| 13 May, 06:28 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 13 May, 06:26 pm | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 13, 2026, titled "Lupin Receives U.S. FDA Approval for Famotidine Injection, USP". | nse |
| 09 May, 01:32 pm | — | … | Lupin Limited has informed the Exchange regarding Copy of Newspaper Publication regarding Audited Financial Results of the Company for the quarter and year ended March 31, 2026 | nse |
| 08 May, 09:22 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | bse |
| 08 May, 09:22 pm | — | … | Lupin Limited has informed the Exchange about Link of the Audio recording of the Earnings Call - Q4 FY26. | nse |
| 07 May, 09:43 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Investor Presentation | bse |
| 07 May, 09:41 pm | — | … | Lupin Limited has informed the Exchange about Investor Presentation | nse |
| 07 May, 09:33 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 07 May, 09:30 pm | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 07, 2026, titled "Lupin FY2026 and Q4 FY2026 Results". | nse |
| 07 May, 09:24 pm | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | bse |
| 07 May, 09:20 pm | — | … | Lupin Limited has informed the Exchange regarding Change in Auditors of the company. | nse |
| 07 May, 09:15 pm | — | … | Lupin Ltd - 500257 - Corporate Action-Board approves Dividend | bse |
| 07 May, 09:10 pm | — | … | Lupin Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs. 18 per equity share. | nse |
| 07 May, 08:58 pm | — | … | Lupin Limited has submitted to the Exchange, the Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each fully paid up for the Financial Year ended March 31, 2026. | nse |
| 07 May, 08:50 pm | — | … | Lupin Ltd - 500257 - Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31, 2026 And Recommend Final Dividend Of Rs. 18/- Per Equity Share I.E. 900% Of The Face Value Of Rs. 2/- Each Fully Paid Up For The Financial Year Ended March 31, 2026 | bse |
| 05 May, 09:11 am | — | … | Lupin Limited has informed the Exchange regarding a press release dated May 05, 2026, titled "Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid". | nse |
| 05 May, 09:08 am | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 28 Apr, 09:18 pm | — | … | Lupin Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | nse |
| 23 Apr, 06:27 pm | — | … | Lupin Limited has informed the Exchange about Schedule of Earnings Call for Q4 FY26. | nse |
| 22 Apr, 10:40 pm | — | … | Lupin Ltd - 500257 - Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2026, And Recommend Dividend, If Any. | bse |
| 22 Apr, 09:13 am | — | … | Lupin Limited has informed the Exchange regarding a press release dated April 22, 2026, titled "Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States". | nse |
| 22 Apr, 09:12 am | — | … | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 18 Apr, 11:57 am | — | … | Lupin Limited has informed the Exchange about U.S. FDA has concluded an inspection at our manufacturing facility located in Somerset, New Jersey, U.S.A. | nse |